Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

However, investors have turned sour on it. Here’s what you need to know: Why Is HIMS Stock Down So Much? HIMS stock plunged by 18% after the FDA news that resolved a shortage of weight-loss ...

Hims & Hers Health's revenue grew 69% YoY, boosting its outlook. See why HIMS stock’s growth potential and high implied ...

Here’s what you need to know: Why is HIMS Stock Up So Much Today? HIMS stock is up significantly after a successful high-profile Super Bowl ad. Its $7 million ad spotlighting compounded ...

With Hims & Her's main source of growth set to be extinguished, Citi analysts said its full-year guidance appears "aspirational." ...

Many treatments are available, and with the popularity of online and mail-order services in recent years, two leaders are BlueChew and Hims. Both companies offer different ED treatments and a ...

Hims & Hers saw a massive YTD surge, but FDA news led to a pullback. Find out why HIMS stock is still undervalued and why ...

Hims & Hers Health ( HIMS -12.56%) stock took a tumble Thursday morning, falling 9.2% through 11:40 a.m. ET on some ...

Shares of Hims & Hers Health Inc. (NYSE: HIMS) have made a splash in recent weeks, reaching a new all-time high of just under ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

The stock price of Hims & Hers Health (NYSE: HIMS), a telehealth platform, has risen a stellar 43% in a week. Much of this move came after the company’s controversial Super Bowl commercial ...

With the FDA shutting down its key revenue stream, Hims faces a tough road ahead--can it justify its valuation?